Pathophysiological and diagnostic implications of cortical dysfunction in ALS

Nature Reviews Neurology

Volumn 12, Issue 11, 2016, Pages 651-661

  Geevasinga, Nimeshan ^a   Menon, Parvathi ^a   Özdinler, P Hande ^b   Kiernan, Matthew C ^a   Vucic, Steve ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN DYSFUNCTION; C9ORF72 GENE; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL RESEARCH; CORTICAL DYSFUNCTION; DISEASE COURSE; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; GENE; HUMAN; MOTONEURON; NERVE DEGENERATION; NEUROIMAGING; NONHUMAN; NUCLEOTIDE REPEAT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CORTICAL EXCITABILITY; GENETICS; PATHOLOGY; PHYSIOLOGY;

GUANINE NUCLEOTIDE EXCHANGE C9ORF72;

AMYOTROPHIC LATERAL SCLEROSIS; C9ORF72 PROTEIN; CORTICAL EXCITABILITY; HUMANS; MOTOR NEURONS;

EID: 84988603515     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.140     Document Type: Review

References (139)

1. Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942-955 (2011).
2. Vucic, S., Rothstein, J. D. & Kiernan, M. C. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 37, 433-442 (2014).
3. Eisen, A., Kim, S. & Pant, B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve 15, 219-224 (1992).
4. Geevasinga, N. et al. Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia. Eur. J. Neurol. 22, 826-831, e57-e58 (2015).
5. Vucic, S. & Kiernan, M. C. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 78, 849-852 (2007).
6. Williamson, T. L. & Cleveland, D. W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 2, 50-56 (1999).
7. Fischer, L. R. et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232-240 (2004).
8. Ravits, J., Paul, P. & Jorg, C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68, 1571-1575 (2007).
9. Charcot, J. & Joffroy, A. Deux cas d'atrophie musculaire progressive avec lesion de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch. Physiol. Neurol. Pathol. 2, 744-754 (in French ) (1869).
10. Nihei, K., McKee, A. C. & Kowall, N. W. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol. 86, 55-64 (1993).
11. Zhang, W. et al. Hyperactive somatostatin interneurons contribute to excitotoxicity in neurodegenerative disorders. Nat. Neurosci. 19, 557-559 (2016).
12. Eisen, A. & Weber, M. The motor cortex and amyotrophic lateral sclerosis. Muscle Nerve 24, 564-573 (2001).
13. Hirota, N., Eisen, A. & Weber, M. Complex fasciculations and their origin in amyotrophic lateral sclerosis and Kennedy's disease. Muscle Nerve 23, 1872-1875 (2000).
14. Devine, M. S., Kiernan, M. C., Heggie, S., McCombe, P. A. & Henderson, R. D. Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 481-487 (2014).
15. Al?Chalabi, A. et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 13, 1108-1113 (2014).
16. Eisen, A., Kiernan, M., Mitsumoto, H. & Swash, M. Amyotrophic lateral sclerosis: a long preclinical period? J. Neurol. Neurosurg. Psychiatry 85, 1232-1238 (2014).
17. Heath, P. R. & Shaw, P. J. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26, 438-458 (2002).
18. Dong, H. et al. Characterization of the glutamate receptor-interacting proteins GRIP1 and GRIP2. J. Neurosci. 19, 6930-6941 (1999).
19. Vandenberg, R. J. Molecular pharmacology and physiology of glutamate transporters in the central nervous system. Clin. Exp. Pharmacol. Physiol. 25, 393-400 (1998).
20. Simeone, T. A., Sanchez, R. M. & Rho, J. M. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J. Child Neurol. 19, 343-360 (2004).
21. Spalloni, A., Nutini, M. & Longone, P. Role of the N?methyl-d?aspartate receptors complex in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1832, 312-322 (2013).
22. Jaiswal, M. K. Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation. Mol. Cell. Ther. 2, 26 (2014).
23. Jiang, M., Schuster, J. E., Fu, R., Siddique, T. & Heckman, C. J. Progressive changes in synaptic inputs to motoneurons in adult sacral spinal cord of a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 29, 15031-15038 (2009).
24. Urushitani, M. et al. N?methyl-d?aspartate receptormediated mitochondrial Ca2+ overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca2+ influx. J. Neurosci. Res. 63, 377-387 (2001).
25. Sanelli, T., Ge, W., Leystra-Lantz, C. & Strong, M. J. Calcium mediated excitotoxicity in neurofilament aggregate-bearing neurons in vitro is NMDA receptor dependant. J. Neurol. Sci. 256, 39-51 (2007).
26. Van Damme, P., Braeken, D., Callewaert, G., Robberecht, W. & Van Den Bosch, L. GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 64, 605-612 (2005).
27. Kwak, S. & Kawahara, Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J. Mol. Med. 83, 110-120 (2005).
28. Takuma, H., Kwak, S., Yoshizawa, T. & Kanazawa, I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann. Neurol. 46, 806-815 (1999).
29. Boillee, S., Vande Velde, C. & Cleveland, D. W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59 (2006).
30. Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R. W. Selective loss of glial glutamate transporter GLT?1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73-84 (1995).
31. Trotti, D., Rolfs, A., Danbolt, N. C., Brown, R. H. Jr & Hediger, M. A. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 2, 427-433 (1999).
32. Boston-Howes, W. et al. Caspase?3 cleaves and inactivates the glutamate transporter EAAT2. J. Biol. Chem. 281, 14076-14084 (2006).
33. Gibb, S. L. et al. A caspase-3?cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1?linked amyotrophic lateral sclerosis. J. Biol. Chem. 282, 32480-32490 (2007).
34. Rothstein, J. D. et al. Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77 (2005).
35. Pieri, M., Carunchio, I., Curcio, L., Mercuri, N. B. & Zona, C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp. Neurol. 215, 368-379 (2009).
36. Saba, L. et al. Altered functionality, morphology, and vesicular glutamate transporter expression of cortical motor neurons from a presymptomatic mouse model of amyotrophic lateral sclerosis. Cereb. Cortex 26, 1512-1528 (2016).
37. Fogarty, M. J., Noakes, P. G. & Bellingham, M. C. Motor cortex layer V pyramidal neurons exhibit dendritic regression, spine loss, and increased synaptic excitation in the presymptomatic hSOD1G93A mouse model of amyotrophic lateral sclerosis. J. Neurosci. 35, 643-647 (2015).
38. Jara, J. H., Villa, S. R., Khan, N. A., Bohn, M. C. & Özdinler, P. H. AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite degeneration in ALS. Neurobiol. Dis. 47, 174-183 (2012).
39. Özdinler, P. H. et al. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G93A transgenic ALS mice. J. Neurosci. 31, 4166-4177 (2011).
40. Kuo, J. J. et al. Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J. Neurophysiol. 91, 571-575 (2004).
41. Lemon, R. N. & Griffiths, J. Comparing the function of the corticospinal system in different species: organizational differences for motor specialization? Muscle Nerve 32, 261-279 (2005).
42. Imbrici, P., D'Adamo, M. C., Kullmann, D. M. & Pessia, M. Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4?1.1/Kv?1.1 and Kv1.4?1.1/Kv?1.2. Eur. J. Neurosci. 24, 3073-3083 (2006).
43. Jara, J. H., Genc, B., Klessner, J. L. & Ozdinler, P. H. Retrograde labeling, transduction, and genetic targeting allow cellular analysis of corticospinal motor neurons: implications in health and disease. Front. Neuroanat. 8, 16 (2014).
44. Jara, J. H. et al. Corticospinal motor neurons are susceptible to increased ER stress and display profound degeneration in the absence of UCHL1 function. Cereb. Cortex 25, 4259-4272 (2015).
45. Wainger, B. J. et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7, 1-11 (2014).
46. Devlin, A. C. et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat. Commun. 6, 5999 (2015).
47. Naujock, M. et al. 4?Aminopyridine induced activity rescues hypoexcitable motor neurons from amyotrophic lateral sclerosis patient-derived induced pluripotent stem cells. Stem Cells 34, 1563-1575 (2016).
48. Kuo, J. J., Siddique, T., Fu, R. & Heckman, C. J. Increased persistent Na+ current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J. Physiol. 563, 843-854 (2005).
49. Kanai, K. et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 129, 953-962 (2006).
50. Vucic, S. & Kiernan, M. C. Upregulation of persistent sodium conductances in familial ALS. J. Neurol. Neurosurg. Psychiatry 81, 222-227 (2010).
51. Menon, P., Kiernan, M. C. & Vucic, S. ALS pathophysiology: insights form the split-hand phenomenon. Clin. Neurophysiol. 125, 186-193 (2014).
52. Geevasinga, N. et al. Axonal ion channel dysfunction in C9orf72 familial amyotrophic lateral sclerosis. JAMA Neurol. 72, 49-57 (2015).
53. van Es, M. A. et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genomewide association study. Lancet Neurol. 6, 869-877 (2007).
54. Ince, P. et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. 19, 291-299 (1993).
55. Amendola, J. & Durand, J. Morphological differences between wild-type and transgenic superoxide dismutase 1 lumbar motoneurons in postnatal mice. J. Comp. Neurol. 511, 329-341 (2008).
56. Quinlan, K. A. Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis. Integr. Comp. Biol. 51, 913-925 (2011).
57. Shaw, P. & Kuncl, R. W. in Motor Neuron Disease (ed. Kuncl, R. W.) 37-73 (W. B. Saunders, 2002).
58. Saxena, S. et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron 80, 80-96 (2013).
59. Leroy, F., Lamotte d'Incamps, B., Imhoff-Manuel, R. D. & Zytnicki, D. Early intrinsic hyperexcitability does not contribute to motoneuron degeneration in amyotrophic lateral sclerosis. eLife 3, e04046 (2014).
60. Haidet-Phillips, A. M. et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824-828 (2011).
61. Li, W. et al. Human endogenous retrovirus?K contributes to motor neuron disease. Sci. Transl Med. 7, 307ra153 (2015).
62. Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P. & Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347, 1425-1431 (1996).
63. Bensimon, G., Lacomblez, L. & Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330, 585-591 (1994).
64. Vucic, S. et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 136, 1361-1370 (2013).
65. Higgins, C. M., Jung, C. & Xu, Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 4, 16 (2003).
66. Kirkinezos, I. G. et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A?SOD1 mice. J. Neurosci. 25, 164-172 (2005).
67. Lederer, C. W., Torrisi, A., Pantelidou, M., Santama, N. & Cavallaro, S. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 8, 26 (2007).
68. Xu, Z., Jung, C., Higgins, C., Levine, J. & Kong, J. Mitochondrial degeneration in amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 36, 395-399 (2004).
69. Dugan, L. L. & Choi, D. W. Excitotoxicity, free radicals, and cell membrane changes. Ann. Neurol. 35, S17-S21 (1994).
70. Bowling, A. C. & Beal, M. F. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56, 1151-1171 (1995).
71. Comi, G. P. et al. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann. Neurol. 43, 110-116 (1998).
72. Li, Q. et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc. Natl Acad. Sci. USA 107, 21146-21151 (2010).
73. Bilsland, L. G. et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc. Natl Acad. Sci. USA 107, 20523-20528 (2010).
74. MacAskill, A. F. et al. Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron 61, 541-555 (2009).
75. Menon, P., Kiernan, M. & Vucic, S. Biomarkers and future targets for development in amyotrophic lateral sclerosis. Curr. Med. Chem. 21, 3535-3550 (2014).
76. Bogdanov, M. B., Ramos, L. E., Xu, Z. & Beal, M. F. Elevated hydroxyl radical generation in vivo in an animal model of amyotrophic lateral sclerosis. J. Neurochem. 71, 1321-1324 (1998).
77. Abe, K. et al. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol. Res. 19, 124-128 (1997).
78. Beal, M. F. et al. Increased 3?nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42, 644-654 (1997).
79. Hensley, K. et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A?SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid. Redox Signal. 8, 2075-2087 (2006).
80. Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21?linked ALS-FTD. Neuron 72, 257-268 (2011).
81. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p?linked FTD and ALS. Neuron 72, 245-256 (2011).
82. Majounie, E. et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323-330 (2012).
83. Turner, M. R. et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12, 310-322 (2013).
84. Al?Sarraj, S. et al. p62 positive, TDP?43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 122, 691-702 (2011).
85. Burrell, J. R., Kiernan, M. C., Vucic, S. & Hodges, J. R. Motor neuron dysfunction in frontotemporal dementia. Brain 134, 2582-2594 (2011).
86. Burrell, J. R. et al. The frontotemporal dementia-motor neuron disease continuum. Lancet http://dx.doi.org/10.1016/S0140-6736(16)00737-6 (2016).
87. Di Lazzaro, V. et al. Transcranial direct current stimulation effects on the excitability of corticospinal axons of the human cerebral cortex. Brain Stimul. 6, 641-643 (2013).
88. Vucic, S., Ziemann, U., Eisen, A., Hallett, M. & Kiernan, M. C. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J. Neurol. Neurosurg. Psychiatry 84, 1161-1170 (2013).
89. Chen, R. et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin. Neurophysiol. 119, 504-532 (2008).
90. Kiers, L., Cros, D., Chiappa, K. H. & Fang, J. Variability of motor potentials evoked by transcranial magnetic stimulation. Electroencephalogr. Clin. Neurophysiol. 89, 415-423 (1993).
91. Fisher, R. J., Nakamura, Y., Bestmann, S., Rothwell, J. C. & Bostock, H. Two phases of intracortical inhibition revealed by transcranial magnetic threshold tracking. Exp. Brain Res. 143, 240-248 (2002).
92. Vucic, S., Howells, J., Trevillion, L. & Kiernan, M. C. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve 33, 477-486 (2006).
93. Stefan, K., Kunesch, E., Benecke, R. & Classen, J. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann. Neurol. 49, 536-539 (2001).
94. Zanette, G. et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin. Neurophysiol. 113, 1688-1697 (2002).
95. Vucic, S. & Kiernan, M. C. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 129, 2436-2446 (2006).
96. Vucic, S. & Kiernan, M. C. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin. Neurophysiol. 119, 1088-1096 (2008).
97. Vucic, S., Nicholson, G. A. & Kiernan, M. C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 131, 1540-1550 (2008).
98. Menon, P. et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 14, 478-484 (2015).
99. Menon, P., Kiernan, M. C. & Vucic, S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin. Neurophysiol. 126, 803-809 (2015).
100. Menon, P., Geevasinga, N., Yiannikas, C., Kiernan, M. C. & Vucic, S. Cortical contributions to the flail leg syndrome: pathophysiological insights. Amyotroph. Lateral Scler. Frontotemporal Degener. 17, 389-396 (2016).
101. Williams, K. L. et al. Pathophysiological insights into ALS with C9ORF72 expansions. J. Neurol. Neurosurg. Psychiatry 84, 931-935 (2013).
102. Geevasinga, N. et al. Cortical function in asymptomatic carriers and patients with C9orf72 amyotrophic lateral sclerosis. JAMA Neurol. 72, 1268-1274 (2015).
103. Blair, I. P. et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J. Neurol. Neurosurg. Psychiatry 81, 1286-1288 (2010).
104. Vucic, S., Cheah, B. C., Yiannikas, C. & Kiernan, M. C. Cortical excitability distinguishes ALS from mimic disorders. Clin. Neurophysiol. 122, 1860-1866 (2011).
105. Vucic, S., Nicholson, G. A. & Kiernan, M. C. Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS. J. Neurol. Neurosurg. Psychiatry 81, 97-100 (2010).
106. Turner, M. R. et al. Neuroimaging in amyotrophic lateral sclerosis. Biomark. Med. 6, 319-337 (2012).
107. Verstraete, E. et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 83, 383-388 (2012).
108. Walhout, R. et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J. Neurol. Neurosurg. Psychiatry 86, 288-294 (2015).
109. van der Graaff, M. M. et al. Upper and extramotoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain 134, 1211-1228 (2011).
110. Zarei, M. et al. Two-dimensional population map of cortical connections in the human internal capsule. J. Magn. Reson. Imaging 25, 48-54 (2007).
111. Menke, R. L. et al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch. Neurol. 69, 1493-1498 (2012).
112. Sarro, L. et al. Cognitive functions and white matter tract damage in amyotrophic lateral sclerosis: a diffusion tensor tractography study. AJNR Am. J. Neuroradiol. 32, 1866-1872 (2011).
113. Walhout, R. et al. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology 85, 1780-1788 (2015).
114. Verstraete, E., Veldink, J. H., Mandl, R. C., van den Berg, L. H. & van den Heuvel, M. P. Impaired structural motor connectome in amyotrophic lateral sclerosis. PLoS ONE 6, e24239 (2011).
115. Verstraete, E., Veldink, J. H., van den Berg, L. H. & van den Heuvel, M. P. Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis. Hum. Brain Mapp. 35, 1351-1361 (2014).
116. Schmidt, R., de Reus, M. A., Scholtens, L. H., van den Berg, L. H. & van den Heuvel, M. P. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. Neuroimage 124, 762-769 (2016).
117. Eisen, A. A. & Shtybel, W. AAEM minimonograph #35: clinical experience with transcranial magnetic stimulation. Muscle Nerve 13, 995-1011 (1990).
118. Wilbourn, A. J. The split hand syndrome. Muscle Nerve 23, 138 (2000).
119. Kuwabara, S. et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity. Muscle Nerve 37, 426-430 (2008).
120. Menon, P., Kiernan, M. C. & Vucic, S. Cortical dysfunction underlies the development of the splithand in amyotrophic lateral sclerosis. PLoS ONE 9, e87124 (2014).
121. Menon, P., Kiernan, M. C. & Vucic, S. Cortical excitability differences in hand muscles follow a splithand pattern in healthy controls. Muscle Nerve 49, 836-844 (2014).
122. Menon, P., Bae, J. S., Mioshi, E., Kiernan, M. C. & Vucic, S. Split-hand plus sign in ALS: differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 315-318 (2013).
123. Bae, J. S., Menon, P., Mioshi, E., Kiernan, M. C. & Vucic, S. Cortical hyperexcitability and the split-hand plus phenomenon: pathophysiological insights in ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 250-256 (2014).
124. Turner, M. R. et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 82, 853-854 (2011).
125. Reid, C. S. & Serrien, D. J. Handedness and the excitability of cortical inhibitory circuits. Behav. Brain Res. 230, 144-148 (2012).
126. Brooks, B. R., Miller, R. G., Swash, M. & Munsat, T. L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293-299 (2000).
127. de Carvalho, M. et al. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 119, 497-503 (2008).
128. Brooks, B. R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical limits of amyotrophic lateral sclerosis workshop contributors. J. Neurol. Sci. 124, 96-107 (1994).
129. Turner, M. R., Kiernan, M. C., Leigh, P. N. & Talbot, K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 8, 94-109 (2009).
130. Traynor, B. et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch. Neurol. 57, 1171-1176 (2000).
131. Paganoni, S. et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 453-456 (2014).
132. Costa, J., Swash, M. & de Carvalho, M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch. Neurol. 69, 1410-1416 (2012).
133. Swash, M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry 83, 659-662 (2012).
134. Higashihara, M. et al. Fasciculation potentials in amyotrophic lateral sclerosis and the diagnostic yield of the Awaji algorithm. Muscle Nerve 45, 175-182 (2012).
135. Geevasinga, N., Menon, P., Yiannikas, C., Kiernan, M. C. & Vucic, S. Diagnostic utility of cortical excitability studies in amyotrophic lateral sclerosis. Eur. J. Neurol. 21, 1451-1457 (2014).
136. Komissarow, L. et al. Triple stimulation technique (TST) in amyotrophic lateral sclerosis. Clin. Neurophysiol. 115, 356-360 (2004).
137. Turner, M. R. & Verstraete, E. What does imaging reveal about the pathology of amyotrophic lateral sclerosis? Curr. Neurol. Neurosci. Rep. 15, 45 (2015).
138. Filippi, M. et al. Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 14, 786-788 (2015).
139. Grieve, S. M. et al. Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 17, 85-92 (2015).